Chapter 5 of Bridging the GAP has the following learning objectives: 

1. To be aware of psychiatric comorbidities commonly associated with ADHD in adults  
2. To explore the hypothesised underlying neurobiological links between common psychiatric comorbidities and ADHD
3. To understand how to make a differential diagnosis of adult ADHD and other psychiatric disorders with overlapping symptoms  
4. To gain knowledge on how to integrate psychiatric comorbidities into an adult ADHD treatment plan 

Chapter 6 of Bridging the GAP has the following learning objectives: 

1. To be aware of the aims of ‘optimal management of ADHD’ in adults
2. To be able to define and characterise the ‘optimal management’ process (i.e., best practice)
3. To recognise the benefits of treating ADHD in adults in terms of reducing the negative impacts of  ADHD on adults 

Chapter 7 of Bridging the GAP has the following learning objectives: 

1. To be able to identify pharmacological interventions currently licensed for the treatment of adults with ADHD in the UK
2. To understand the clinical implications of the hypothesised modes of action of these pharmacological interventions, their mechanisms of delivery and durations of effect
3. To be aware of potential drug-drug interactions, understand practical tips on how to initiate treatment, and recognise very common and common side effects
4. To understand the places of these pharmacological treatments in clinical guidelines for the management of ADHD in adults 

Chapter 8 of Bridging the GAP has the following learning objectives: 

1. To understand the place for non-pharmacological approaches to the management of ADHD in adults  and be aware of clinical guidelines
2. To understand which non-pharmacological treatments may be useful for adults with ADHD  
3. To gain knowledge of evidence-based non-pharmacological treatment approaches to ADHD in adults 

A series of fictitious case studies to illustrate key learnings from the Bridging the GAP foundation program  

In this video from the Bridging the GAP webinar series, Dr. Uthish Sreedaran describes the increasing global prevalence of ADHD, diagnostic criteria, recognition and appropriate referral pathways in the UK.  

In this video from the autumn 2023 BTG webinar series, Dr Peter Mason describes the aetiology and neurobiology of ADHD.

In this video from the BTG webinar series, Dr. Uthish Sreedaran describes the impact of untreated ADHD.

In this video from the BTG webinar series, Dr. Peter Mason describes the assessment and diagnosis process for adult ADHD in the UK.